GlassScriptPhysician profile
Amita Maibam
NPI 1487020806
$3,959.86
in general payments reported to CMS, 2019-2025
23 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $288 · 2021: $538 · 2022: $641 · 2023: $789 · 2024: $808 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296 · Education: $77.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.85 |
| Education | $77.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $610.11 | 2020-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $508.07 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $481.46 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $376.46 | 2021-2025 | |
| Vifor Pharma, INC. | $310.78 | 2019-2023 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $280.63 | 2021-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $216.66 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $202.33 | 2019-2023 | Rayaldee |
| Akebia Therapeutics INC | $194.17 | 2020-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $148.25 | 2023-2025 | |
| Amgen INC. | $137.52 | 2021-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $78.40 | 2021-2024 | Lupkynis |
| Novo Nordisk INC | $59.35 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Daiichi Sankyo INC. | $53.90 | 2021-2024 | Injectafer |
| Ardelyx, INC. | $50.20 | 2024-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.71 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $45.86 | 2022-2023 | Benlysta |
| Calliditas Therapeutics US INC. | $45.14 | 2025 | Tarpeyo |
| Lilly USA, LLC | $29.98 | 2024-2025 | Jardiance |
| Baxter Healthcare | $24.51 | 2024 | Renal - Acute |
| Ultragenyx Pharmaceutical INC. | $23.78 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.24 | 2023 | Amvuttra |
| Boston Scientific Corporation | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amita Maibam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.